We describe a generic approach to assemble correctly two heavy and two light chains, derived
from two existing antibodies, to form human bivalent bispecific IgG antibodies without use …

The crystal structure of the complete 12 subunit RNA polymerase (pol) II bound to a transcription
bubble and product RNA reveals incoming template and nontemplate DNA, a seven …

The transcription elongation factor TFIIS induces mRNA cleavage by enhancing the intrinsic
nuclease activity of RNA polymerase (Pol) II. We have diffused TFIIS into Pol II crystals and …

The eukaryotic RNA polymerases Pol I, Pol II, and Pol III are the central multiprotein machines
that synthesize ribosomal, messenger, and transfer RNA, respectively. Here we provide a …

RNA polymerase (Pol) II consists of a 10-polypeptide catalytic core and the two-subunit
Rpb4/7 complex that is required for transcription initiation. Previous structures of the Pol II core …

The development of bispecific antibodies has attracted substantial interest, and many
different formats have been described. Those specifically containing an Fc part are mostly …

Therapeutic antibodies and antibody derivatives comprise the majority of today's biotherapeutics.
Routine methods to generate novel antibodies, such as immunization and phage-…

Here, we investigated the influence of the variable fragment (Fv) of IgG antibodies on the
binding to the neonatal Fc receptor (FcRn) as well as on FcRn-dependent pharmacokinetics (…

Monoclonal antibodies (mAbs) and proteins containing antibody domains are the most
prevalent class of biotherapeutics in diverse indication areas. Today, established techniques …

Beyond potency, a good developability profile is a key attribute of a biological drug.
Selecting and screening for such attributes early in the drug development process can save …